Abstract
The term retinitis pigmentosa (RP) indicates a heterogeneous group of genetic rare ocular diseases in which either rods or cones are prevalently damaged. RP represents the most common hereditary cause of blindness in people from 20 to 60 years old. In general, the different RP forms consist of progressive photo-receptorial neuro-degenerations, which are characterized by variable visual disabilities and considerable socio-sanitary burden. Sometimes, RP patients do not become visually impaired or legally blind until their 40-50 years of age and/or maintain a quite acceptable sight for all their life. Other individuals with RP become completely blind very early or in middle childhood. Although there is no treatment that can effectively cure RP, in some case-series the disease's progression seems to be reducible by specific preventive approaches. In the most part of RP patients, the quality of vision can be considerably increased by means of nanometer-controlled filters. In the present review, the main aspects of the routine clinical and rehabilitative managements for RP patients are described, particularly focusing on the importance of specific referral Centers to practice a real multidisciplinary governance of these dramatic diseases.
Keywords: glaucoma, photophobia, neurodegeneration, rehabilitation, herapy, prevention, clinical governance, multidisciplinary management, retinitis pigmentosa, Inherited retinal dystrophies
Current Genomics
Title: Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date
Volume: 12 Issue: 4
Author(s): Katia De Nadai, Mario R. Romano, Andrea Binotto, Ciro Costagliola, Giovanni Sato and Francesco Parmeggiani
Affiliation:
Keywords: glaucoma, photophobia, neurodegeneration, rehabilitation, herapy, prevention, clinical governance, multidisciplinary management, retinitis pigmentosa, Inherited retinal dystrophies
Abstract: The term retinitis pigmentosa (RP) indicates a heterogeneous group of genetic rare ocular diseases in which either rods or cones are prevalently damaged. RP represents the most common hereditary cause of blindness in people from 20 to 60 years old. In general, the different RP forms consist of progressive photo-receptorial neuro-degenerations, which are characterized by variable visual disabilities and considerable socio-sanitary burden. Sometimes, RP patients do not become visually impaired or legally blind until their 40-50 years of age and/or maintain a quite acceptable sight for all their life. Other individuals with RP become completely blind very early or in middle childhood. Although there is no treatment that can effectively cure RP, in some case-series the disease's progression seems to be reducible by specific preventive approaches. In the most part of RP patients, the quality of vision can be considerably increased by means of nanometer-controlled filters. In the present review, the main aspects of the routine clinical and rehabilitative managements for RP patients are described, particularly focusing on the importance of specific referral Centers to practice a real multidisciplinary governance of these dramatic diseases.
Export Options
About this article
Cite this article as:
De Nadai Katia, R. Romano Mario, Binotto Andrea, Costagliola Ciro, Sato Giovanni and Parmeggiani Francesco, Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date, Current Genomics 2011; 12 (4) . https://dx.doi.org/10.2174/138920211795860125
DOI https://dx.doi.org/10.2174/138920211795860125 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Current Genomics The Molecular Pathology of Huntingtons Disease (HD)
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Parkinson's Disease: From Genetics to Clinical Practice
Current Genomics Genetic Susceptibility to Prion Diseases in Humans and Mice
Current Genomics NAD Precursors, Mitochondria Targeting Compounds and ADP-Ribosylation Inhibitors in Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry Editorial: New Avenues and Therapeutic Strategies for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design NMDA-antagonism (Memantine): An Alternative Pharmacological Therapeutic Principle in Alzheimers and Vascular Dementia
Current Pharmaceutical Design Differential Retinal Protein Expressions During form Deprivation Myopia in Albino Guinea Pigs
Current Proteomics De Novo and Molecular Target-Independent Discovery of Orally Bioavailable Lead Compounds for Neurological Disorders
Current Alzheimer Research Thienyl Pyrimidine Derivatives with PrPSc Oligomer-Inducing Activity are a Promising Tool to Study Prions
Current Topics in Medicinal Chemistry Oxidative Stress and Altered Mitochondrial Function in Neurodegenerative Diseases: Lessons From Mouse Models
CNS & Neurological Disorders - Drug Targets Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease
Current Alzheimer Research Therapeutic Strategies for Huntingtons Disease: From the Bench to the Clinic
Current Psychopharmacology Emerging Targets and Latest Proteomics Based Therapeutic Approaches in Neurodegenerative Diseases
Current Protein & Peptide Science Synthesis of New Tetra Triazole Functionalized Calix[4]resorcinarene and Chemosensing of Copper Ions in Aqueous Medium
Current Organic Chemistry Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience Transcranial Direct Current Stimulation for the Treatment of Refractory Symptoms of Schizophrenia. Current Evidence and Future Directions
Current Pharmaceutical Design Mitochondria-Targeted Antioxidant Peptides
Current Pharmaceutical Design Relationship between chronic disturbance of 2,3-diphosphoglycerate metabolism in erythrocytes and Alzheimer disease
CNS & Neurological Disorders - Drug Targets